Clinical Trial Update: Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating cadonilimab plus albumin-paclitaxel, cisplatin, and fluorouracil for resectable locally advanced esophageal squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Albumin Paclitaxel (nab-paclitaxel)
• CISPLATIN (cisplatin)
• Cadonilimab
• FLUOROURACIL (Fluorouracil)

Snippet

Sponsor: Weijia Fang, MD | Conditions: The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC | Phase 2 | Status: UNKNOWN